Search research articles
Contact Us
Filters
Showing results (71-80 of 135) with videos related to
Page
of 14
Sort By:
Nature
|
April 17, 2012
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C Smith, Qi Wang, Chen-Shan Chin, et al.
Leukemia Research
|
September 17, 2025
Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbidities
J Preston Claiborne, Daniel Li, Hua-Ling Tsai, et al.
Haematologica
|
December 15, 2022
CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine
Theodoros Karantanos, Patric Teodorescu, Marios Arvanitis, et al.
Haematologica
|
September 21, 2023
Outcome heterogeneity of <i>TP53</i>-mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation
Sergiu Pasca, Saurav D Haldar, Alexander Ambinder, et al.
Blood Neoplasia
|
September 15, 2025
Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML
Andrew D Zale, Venkata Preetam Sandeep Kaduluri, Jonathan A Webster, et al.
Blood Advances
|
December 16, 2017
Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide
Yvette L Kasamon, Richard F Ambinder, Ephraim J Fuchs, et al.
Archives of Pathology & Laboratory Medicine
|
September 2, 2025
QuANTUM-First: Clinical Validation of the LeukoStrat Companion Diagnostic for the Selection of Patients With Acute Myeloid Leukemia Harboring FMS-Like Tyrosine Kinase 3-Internal Tandem Duplications for Treatment With Quizartinib
Jaime E Connolly Rohrbach, Ken C N Chang, Maha Karnoub, et al.
Blood Advances
|
April 25, 2020
A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia
Catherine C Smith, Mark J Levis, Olga Frankfurt, et al.
Blood Advances
|
October 17, 2017
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with <i>FLT3</i>-mutated acute myeloid leukemia: CALGB 11001
Geoffrey L Uy, Sumithra J Mandrekar, Kristina Laumann, et al.
Haematologica
|
October 4, 2024
Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax/ hypomethylating agents
Sabine Kayser, Khaled Sanber, Giovanni Marconi, et al.
Page
of 14
Search research articles
Search
Showing results (71-80 of 135) with videos related to
Sort By:
Page
of 14
Nature
|
April 17, 2012
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C Smith, Qi Wang, Chen-Shan Chin, et al.
Leukemia Research
|
September 17, 2025
Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbidities
J Preston Claiborne, Daniel Li, Hua-Ling Tsai, et al.
Haematologica
|
December 15, 2022
CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine
Theodoros Karantanos, Patric Teodorescu, Marios Arvanitis, et al.
Haematologica
|
September 21, 2023
Outcome heterogeneity of <i>TP53</i>-mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation
Sergiu Pasca, Saurav D Haldar, Alexander Ambinder, et al.
Blood Neoplasia
|
September 15, 2025
Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML
Andrew D Zale, Venkata Preetam Sandeep Kaduluri, Jonathan A Webster, et al.
Blood Advances
|
December 16, 2017
Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide
Yvette L Kasamon, Richard F Ambinder, Ephraim J Fuchs, et al.
Archives of Pathology & Laboratory Medicine
|
September 2, 2025
QuANTUM-First: Clinical Validation of the LeukoStrat Companion Diagnostic for the Selection of Patients With Acute Myeloid Leukemia Harboring FMS-Like Tyrosine Kinase 3-Internal Tandem Duplications for Treatment With Quizartinib
Jaime E Connolly Rohrbach, Ken C N Chang, Maha Karnoub, et al.
Blood Advances
|
April 25, 2020
A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia
Catherine C Smith, Mark J Levis, Olga Frankfurt, et al.
Blood Advances
|
October 17, 2017
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with <i>FLT3</i>-mutated acute myeloid leukemia: CALGB 11001
Geoffrey L Uy, Sumithra J Mandrekar, Kristina Laumann, et al.
Haematologica
|
October 4, 2024
Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax/ hypomethylating agents
Sabine Kayser, Khaled Sanber, Giovanni Marconi, et al.
Page
of 14